<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9C932CFE-AAE2-4A8F-A53F-1C7EAC961997"><gtr:id>9C932CFE-AAE2-4A8F-A53F-1C7EAC961997</gtr:id><gtr:name>Harvard University</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/23D04EC2-3A05-4711-B472-F29894825709"><gtr:id>23D04EC2-3A05-4711-B472-F29894825709</gtr:id><gtr:name>Institute of Zoology</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/53A8F4B4-EBD0-4199-B24B-B5008112311D"><gtr:id>53A8F4B4-EBD0-4199-B24B-B5008112311D</gtr:id><gtr:name>Guy's Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/17BF6965-68C3-4560-8BC2-28AC2D489890"><gtr:id>17BF6965-68C3-4560-8BC2-28AC2D489890</gtr:id><gtr:name>University of Virginia</gtr:name><gtr:address><gtr:line1>P.O. Box 3818</gtr:line1><gtr:postCode>22903</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/C1ED9692-B6AE-4778-BF31-AE813E8E4415"><gtr:id>C1ED9692-B6AE-4778-BF31-AE813E8E4415</gtr:id><gtr:name>MRC Prion Unit</gtr:name><gtr:address><gtr:line1>MRC Prion Unit</gtr:line1><gtr:line2>Institute of Neurology</gtr:line2><gtr:line3>Queen Square</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>WC1N 3BG</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C1ED9692-B6AE-4778-BF31-AE813E8E4415"><gtr:id>C1ED9692-B6AE-4778-BF31-AE813E8E4415</gtr:id><gtr:name>MRC Prion Unit</gtr:name><gtr:address><gtr:line1>MRC Prion Unit</gtr:line1><gtr:line2>Institute of Neurology</gtr:line2><gtr:line3>Queen Square</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>WC1N 3BG</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9C932CFE-AAE2-4A8F-A53F-1C7EAC961997"><gtr:id>9C932CFE-AAE2-4A8F-A53F-1C7EAC961997</gtr:id><gtr:name>Harvard University</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/23D04EC2-3A05-4711-B472-F29894825709"><gtr:id>23D04EC2-3A05-4711-B472-F29894825709</gtr:id><gtr:name>Institute of Zoology</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/53A8F4B4-EBD0-4199-B24B-B5008112311D"><gtr:id>53A8F4B4-EBD0-4199-B24B-B5008112311D</gtr:id><gtr:name>Guy's Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/17BF6965-68C3-4560-8BC2-28AC2D489890"><gtr:id>17BF6965-68C3-4560-8BC2-28AC2D489890</gtr:id><gtr:name>University of Virginia</gtr:name><gtr:address><gtr:line1>P.O. Box 3818</gtr:line1><gtr:postCode>22903</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/41884E82-F651-4B17-AE40-2FE25AE59653"><gtr:id>41884E82-F651-4B17-AE40-2FE25AE59653</gtr:id><gtr:firstName>Peter</gtr:firstName><gtr:surname>Kloehn</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_U123182016"><gtr:id>3981936F-46FB-4BFA-BE97-C4EDD9EC8025</gtr:id><gtr:title>Cellular mechanisms of prion propagation</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_U123182016</gtr:grantReference><gtr:abstractText>Prions are infectious agents that cause the lethal brain disease CJD in humans and they infect a range of different cells in the body. Most studies of prions have required use of laboratory animals but more recently it has been possible to produce types of cells that can be grown indefinitely in the laboratory and used to propagate prions. However, it turns out to be very difficult to find cells that will propagate prions efficiently in the laboratory and the ones that do typically will only propagate just one type, or strain, of prions. By studying different lines of cells that are highly susceptible or poorly susceptible to defined prion strains, we aim to work out the crucial factors in these cells that make them susceptible or resistant. We also want to understand how prions pass from cell to cell. Such knowledge will help us develop better cell systems to study prions (and thereby reduce the need to use animals) and also provide fundamental insights into the mechanisms of prion propagation that will help us develop better tests and treatments for these diseases in the future.</gtr:abstractText><gtr:technicalSummary>The objectives of this programme are (a) to identify cellular susceptibility factors required for the propagation of prions, (b) to characterise the mode of prion spread in the lymphoreticular system of mice.||(a) Cell lines have been recognized as a very useful tool for prion detection and assay, since the cell-based amplification of prions increases sensitivity levels by about 3-4 orders of magnitude as compared to conventional protein assays. To date, the number of cell lines in which prions can be propagated long term is very limited. In addition the majority of prion-susceptible cell lines are permissive only to one or two mouse-adapted prion strains, but not to ovine, bovine or human prions. Understanding the cellular factors mediating prion propagation is of major importance to the field. To identify cellular susceptibility factors we selected revertants from highly susceptible cells that showed about 100-fold lower rates of prion propagation. We are using Affymetrix microarrays to identify differentially expressed genes between highly susceptible cells and revertants. To validate potential gene candidates we are using state-of the art gene intervention methods in a tetracycline (Tet)-inducible fashion to exclude confounding clonal effects.||(b) In most transmissible spongiform encephalopathies (TSE) prions accumulate in the lymphoreticular system (LRS) long before they are detectable in the central nervous system. A considerable body of evidence demonstrates that the transfer of infectivity between hematopoietic and non-hematopoietic cells is essential for neuroinvasion of prions. However, the molecular mode by which prions are transferred between different cells is ill-defined. Recently in-vitro studies demonstrated that prions are released into the cell supernatant in form of exosomes, a secretion process that has been well characterised in hematopoietic cells. We could demonstrate the release of infectivity from scrapie-infected cells to spatially separated non-infected cells via the external medium using the Scrapie-cell assay, a quantitative cell-based infectivity assay that we developed. We are now testing whether infectivity is released by antigen-presenting cells from the LRS of scrapie-infected mice. A variety of potentially infectious cells, like B-and T-cells, dendritic cells, macrophages and follicular dendritic cells are isolated by immunolabelling (MACS separation) and infectious titres and the release of infectivity are determined subsequently. Although the biological function of exosomes has not yet been elucidates, novel findings suggest a role in antigen presentation and immune response. It has been demonstrated that exosomes from dendritic cells (DC) that were loaded with tumour-proteins from melanomas ex vivo triggered a T-cell response when re-injected into tumour-bearing mice. In analogy we will test whether exosomes isolated from DC of scrapie-infected mice trigger a T cell response in vitro and in vivo. If this is the case the therapeutic effect of DC-derived exosomes will be tested in vivo by injecting purified exosomes into scrapie-infected animals and incubation times will be determined in parallel to mock-treated mice.</gtr:technicalSummary><gtr:fund><gtr:end>2017-05-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2005-04-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>5025245</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Virginia (UVa)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Monoclonal antibodies against Iqgap2</gtr:description><gtr:id>638C8E9D-F50A-4C88-9058-E5801FC34B4E</gtr:id><gtr:impact>Publication (PMID: 24843046) was outcome of this partnership</gtr:impact><gtr:outcomeId>545797ca2eb729.51151491-1</gtr:outcomeId><gtr:partnerContribution>Raised antibodies against Iqgap2</gtr:partnerContribution><gtr:piContribution>Gene validation project led to the identification of a link between Iqgap2 expression and prion propagation</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Guy's Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Functional annotation clustering and hierarchical clustering</gtr:description><gtr:id>283FD134-F06F-40D5-84F1-2BEE7C350482</gtr:id><gtr:impact>This data was published in 2014 (PMID: 24843046).</gtr:impact><gtr:outcomeId>54579582b50096.84606508-1</gtr:outcomeId><gtr:partnerContribution>Dr Anita Grigoriadis from the Breakthrough Breast Cancer Research Unit (Research Oncology, Guy's Hospital, London, UK) contributed to the analysis of microarray data and hierarchical clustering.</gtr:partnerContribution><gtr:piContribution>Research outcomes in our laboratory prompted us to seek collaboration with Dr. Grigoriadis.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Statistical Modelling</gtr:description><gtr:id>E4DFC5C3-7939-4773-BA37-C5692D148D6D</gtr:id><gtr:impact>Publication (PMID:22359509)</gtr:impact><gtr:outcomeId>PaMvtnwg2ub-1</gtr:outcomeId><gtr:partnerContribution>Established a Generalised Linear Model to calculate Infectious Titres</gtr:partnerContribution><gtr:piContribution>Provided data for Statistical Modelling</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Harvard University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Harvard Medical School</gtr:department><gtr:description>Amyloid seeding model_Dominic</gtr:description><gtr:id>149FB882-B68B-4178-B8CA-F7EA0DDD6520</gtr:id><gtr:impact>no publishable outcomes</gtr:impact><gtr:outcomeId>58c7e86b4ff1a8.12819584-1</gtr:outcomeId><gtr:partnerContribution>Dominic is actively contributing to a project of ours` which aims to establishing an amyloid seeding model.</gtr:partnerContribution><gtr:piContribution>The Unit has a long-standing research collaboration with Dominic Walsh's group at Harvard Medical School (Laboratory for Neurodegenerative Research, Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115, United States). 
I am providing expertise in cell models to investigate the interaction between amyloid beta and the prion protein. Dominic has recently received a cell line I have generated, N2aPK1 cells. Experiments are in progress to investigate amyloid beta binding to the prion protein in this cell line.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Laboratory for Molecular Cell Biology</gtr:department><gtr:description>Electron and superresolution microscopy of prion infection</gtr:description><gtr:id>84569417-07EF-4BDD-8316-327E2D7EB048</gtr:id><gtr:impact>Ongoing partnership which has not yet resulted in an output</gtr:impact><gtr:outcomeId>56d857b2129656.00277828-1</gtr:outcomeId><gtr:partnerContribution>Technical and scientific consultancy</gtr:partnerContribution><gtr:piContribution>A partnership has been setup with Mark Marsh's laboratory at the LMCB to investigate changes in membrane microdomains upon prion infection.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Zurich</gtr:collaboratingOrganisation><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:department>Institute of Neuropathology</gtr:department><gtr:description>Institute of Neuropathology</gtr:description><gtr:id>0770F6B4-25FF-40EB-A69A-919D00540785</gtr:id><gtr:impact>publication, PubMed ID: 18082765</gtr:impact><gtr:outcomeId>32845A404A4-1</gtr:outcomeId><gtr:partnerContribution>Access to microarray data</gtr:partnerContribution><gtr:piContribution>Provided the prion-susceptible cell line N2aPK1 to investigate differentially expressed genes during prion infection.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Prion-resistant revertants from highly susceptible cells are highly valuable cell lines to identify genes involved prion propagation. The isolation of the cells has been described in Marbiah et al. 2014.</gtr:description><gtr:id>DD2617A1-4C0B-46DE-8BCF-B94FE3EBC494</gtr:id><gtr:impact>The identification of a gene regulatory network by the use of revertants, as specified in Marbiah et al., 2014, has provided an opportunity to test novel therapeutic approaches against prion diseases. Experiments are on-going.</gtr:impact><gtr:outcomeId>56544593ae8d69.91980949</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Prion-resistant revertant cell lines</gtr:title><gtr:type>Cell line</gtr:type><gtr:url>http://emboj.embopress.org/content/33/14/1527</gtr:url></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>PK1-2 cells show improved levels of susceptibility for prion propagation as compared to progenitor cells.</gtr:description><gtr:id>6D1DAA2D-6B5F-4452-B7F7-144766BCF1FF</gtr:id><gtr:impact>no notable impact</gtr:impact><gtr:outcomeId>2328252AB4A</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Prion-susceptible cell lines</gtr:title><gtr:type>Cell line</gtr:type><gtr:yearFirstProvided>2008</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>The characterisation of prions is hampered by difficulties in their detection. We have established a novel method to identify prions in cells based on the delipidation of plasma membranes as described in Marbiah et al. (PMID: 24843046).</gtr:description><gtr:id>B47313F2-380C-4250-AF2F-7E17705A8549</gtr:id><gtr:impact>The in vitro detection of prions opens possibilities to scrutinise the membrane microenvironment of disease-associated prions and facilitates the search for binding partners.</gtr:impact><gtr:outcomeId>56545027af2412.19884723</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Detection of disease-associated prions in cells</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:url>http://emboj.embopress.org/content/33/14/1527</gtr:url><gtr:yearFirstProvided>2015</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>7276EBB7-919B-44B2-A732-E3E628F6C974</gtr:id><gtr:title>Assaying prions in cell culture: the standard scrapie cell assay (SSCA) and the scrapie cell assay in end point format (SCEPA).</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dadde5904c3542020661e7bef4d58a39"><gtr:id>dadde5904c3542020661e7bef4d58a39</gtr:id><gtr:otherNames>Mahal SP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1064-3745</gtr:issn><gtr:outcomeId>15EA6DE94E3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F64734AB-EFBE-46EA-80CE-B8010439FBDA</gtr:id><gtr:title>Exosome release from infected dendritic cells: a clue for a fast spread of prions in the periphery?</gtr:title><gtr:parentPublicationTitle>The Journal of infection</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/545ce42579cf58a78a380cd9bd2cf729"><gtr:id>545ce42579cf58a78a380cd9bd2cf729</gtr:id><gtr:otherNames>Kl?hn PC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0163-4453</gtr:issn><gtr:outcomeId>pm_14806_26_23911964</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8A3F59C8-2559-48AC-8B0F-C8814A404391</gtr:id><gtr:title>IBC's 23rd Annual Antibody Engineering, 10th Annual Antibody Therapeutics international conferences and the 2012 Annual Meeting of The Antibody Society: December 3-6, 2012, San Diego, CA.</gtr:title><gtr:parentPublicationTitle>mAbs</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/545ce42579cf58a78a380cd9bd2cf729"><gtr:id>545ce42579cf58a78a380cd9bd2cf729</gtr:id><gtr:otherNames>Kl?hn PC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1942-0862</gtr:issn><gtr:outcomeId>pm_14806_26_23575266</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E26A88B1-6588-46D1-9A84-166DABCF8802</gtr:id><gtr:title>PrP antibodies do not trigger mouse hippocampal neuron apoptosis.</gtr:title><gtr:parentPublicationTitle>Science (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/545ce42579cf58a78a380cd9bd2cf729"><gtr:id>545ce42579cf58a78a380cd9bd2cf729</gtr:id><gtr:otherNames>Kl?hn PC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0036-8075</gtr:issn><gtr:outcomeId>pm_14806_26_22223800</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>509FC07E-7B8C-4567-B617-25492BF53EE5</gtr:id><gtr:title>A systematic investigation of production of synthetic prions from recombinant prion protein.</gtr:title><gtr:parentPublicationTitle>Open biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7b2740857e0a6a774e56992f6a12381e"><gtr:id>7b2740857e0a6a774e56992f6a12381e</gtr:id><gtr:otherNames>Schmidt C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2046-2441</gtr:issn><gtr:outcomeId>56543c996b03d2.69052856</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8E2E9498-D11E-4E7E-8C0C-3458315B269A</gtr:id><gtr:title>In vitro screen of prion disease susceptibility genes using the scrapie cell assay.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9e14ad7dc46751cc03b82cf6e81f69dc"><gtr:id>9e14ad7dc46751cc03b82cf6e81f69dc</gtr:id><gtr:otherNames>Brown CA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>545792109eda18.75757448</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4867E2A8-E786-4A1F-B8C3-99A9FB6B71BB</gtr:id><gtr:title>Plasmacytoid dendritic cells sequester high prion titres at early stages of prion infection.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c97f07ee95a72aa420e52eec7771229f"><gtr:id>c97f07ee95a72aa420e52eec7771229f</gtr:id><gtr:otherNames>Castro-Seoane R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn><gtr:outcomeId>pm_14806_26_22359509</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D91ADE3F-FDA1-4BE6-9DD4-B5F3529EA27A</gtr:id><gtr:title>Transcriptional stability of cultured cells upon prion infection.</gtr:title><gtr:parentPublicationTitle>Journal of molecular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8bc2917b5ef51fe5035ae1954fb023ae"><gtr:id>8bc2917b5ef51fe5035ae1954fb023ae</gtr:id><gtr:otherNames>Julius C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-2836</gtr:issn><gtr:outcomeId>9DFE586C6E3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B190B85F-F68A-4945-8B48-54215028FDF8</gtr:id><gtr:title>Physical, chemical and kinetic factors affecting prion infectivity.</gtr:title><gtr:parentPublicationTitle>Prion</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e107587b5118dadea420a7a7c6a23acc"><gtr:id>e107587b5118dadea420a7a7c6a23acc</gtr:id><gtr:otherNames>Properzi F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1933-6896</gtr:issn><gtr:outcomeId>58c7c30fc4a3b6.82642895</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6D39962B-103C-40C6-882F-4BE57DFC2F5B</gtr:id><gtr:title>Identification of a gene regulatory network associated with prion replication.</gtr:title><gtr:parentPublicationTitle>The EMBO journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/97127fedeb24cd2340bd14f53f67f94d"><gtr:id>97127fedeb24cd2340bd14f53f67f94d</gtr:id><gtr:otherNames>Marbiah MM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0261-4189</gtr:issn><gtr:outcomeId>54579210c660a4.32656447</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_U123182016</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>